McKesson Corporation

1) Strategy & Leadership - McKesson reported strong fiscal 2026 performance, with an 18% increase in adjusted earnings per diluted share. - The company is focused on strategic growth platforms, including oncology and multispecialty services, which saw significant provider expansion and integration of new businesses like Core Ventures and PRISM Vision. - A planned separation of the Medical-Surgical Solutions segment is progressing, with agreements in place for minority investment from Apollo Funds, expected to unlock shareholder value. - Leadership changes include the retirement of CFO Britt Vitalone, who has been instrumental in the company's financial strategy, achieving over 500% increase in shareholder returns during his tenure.

2) Financial & Segment Results - Fiscal 2026 consolidated revenues reached $403 billion, a 12% increase, with adjusted operating profit growing 15% to $6.5 billion. - Fourth quarter results included: - Revenues of $96.3 billion, up 6% YoY. - Adjusted earnings per diluted share of $11.69, a 16% increase YoY. - North American Pharmaceutical revenues of $79.1 billion, up 3% YoY, with operating profit of $980 million, an 11% increase. - Oncology and multispecialty segment revenues increased 35% to $12.7 billion, with operating profit up 53% to $385 million. - The Prescription Technology Solutions segment saw revenues increase 12% to $1.5 billion, with operating profit growing 13% to $322 million.

3) Operational Plans & Challenges - McKesson's operational focus includes enhancing distribution capabilities and leveraging technology to improve efficiency and patient care. - The company successfully launched a new distribution center in Montreal, incorporating advanced automation to enhance service reliability. - Challenges include navigating the impact of branded pharmaceutical price changes due to the Inflation Reduction Act, which affected revenue growth but did not impact operating profit.

4) Guidance & Outlook - For fiscal 2027, McKesson anticipates adjusted earnings per diluted share in the range of $43.80 to $44.60, representing 12% to 14% growth YoY. - Segment growth expectations include: - North American Pharmaceutical: Revenue growth of 4% to 8%, operating profit growth of 5.5% to 9.5%. - Oncology and multispecialty: Revenue growth of 14.5% to 18.5%, operating profit growth of 13.5% to 17.5%. - Prescription Technology Solutions: Revenue growth of 2.5% to 6.5%, operating profit growth of 11% to 15%. - The company plans to return approximately $5 billion to shareholders through share repurchases in fiscal 2027.

5) Investor Angle & Missing Information - McKesson's strategic focus and disciplined execution position it well for sustained growth and shareholder value creation. - The call did not provide specific details on the anticipated impact of the Medical-Surgical Solutions separation on overall financial performance post-IPO.

Bottom line: McKesson's strong fiscal 2026 results and strategic initiatives, including the planned separation of its Medical-Surgical Solutions segment, position the company for continued growth and value creation for shareholders, with robust guidance for fiscal 2027.